Finch Therapeutics Group, Inc. (Finch), a clinical-stage microbiome therapeutics company, announced today that the U.S. Patent and Trademark Office (USPTO) has issued six new patents to Finch covering its Full-Spectrum Microbiota (FSM) and Rationally-Selected Microbiota […]
Four new studies reported at the Alzheimer’s Association International Conference (AAIC) 2018 in Chicago investigated how the digestive system, including gut and liver functions, may be related to changes in the brain, and to brain […]
A single course of antibiotics early in childhood may increase risk for Type 1 diabetes. This is the finding of a study in mice led by researchers from NYU Medical School and published online July […]
Second Genome, Inc., a leader in the development of novel therapeutics derived from the human microbiome, today announced the appointment of Anupama S. Hoey as chief business officer. In her role, Ms. Hoey will be […]
Immune Advisors, LLC, a California-based company focused on forming, financing, and growing companies in the immunotherapy and regenerative medicine space, announced today publication of a manuscript entitled “Protection from chemotherapy- and antibiotic-mediated dysbiosis of the […]
Beiersdorf AG, Hamburg, Germany, and S-Biomedic NV, Beerse, Belgium, today announced that they have entered into a cooperation to jointly drive the future of skin care via research into skin microbiota. Accordingly, Beiersdorf has taken […]
Researchers have discovered a key link to potentially understanding sleep disorders in children, according to a study just published in the journal PLOS One. In a paper titled “Diurnal oscillations in human salivary microRNA and […]
AgBiome LLC, a private company harnessing the plant microbiome for novel agricultural pest solutions, announced today that it has secured $65 million in Series C financing that will help the company bring novel crop protection […]
Cambridge, Massachusetts, July 10, 2018-Vedanta Biosciences, an affiliate of PureTech Health (LSE: PRTC) developing a new category of therapies for immune-mediated and infectious diseases based on rationally defined consortia of human microbiome-derived bacteria, today announced […]
UAS Labs (Wausau, Wisconsin, USA) is excited to announce their licensing agreement with AceBiome (Gyeonggi-do, South Korea), a recent spin-off of the parent biotechnology company Bioneer (Daejeon, South Korea). This agreement includes the manufacturing and […]
Locus Biosciences Inc., an emerging biotechnology company developing CRISPR-Cas3-engineered precision antibacterial products, announced today its acquisition of EpiBiome, Inc.’s high-throughput bacteriophage (“phage”) discovery platform. Pairing EpiBiome’s powerful phage isolation and characterization capability with Locus’s CRISPR-based […]